---
title: 'Allogeneic CAR T Cell Products Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory
  Large B-Cell Lymphoma: Phase 1 Experience From the ALPHA2/ALPHA Clinical Studies'
date: '2025-02-13'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39946666/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1Rkszs2HVZ2RHP33OibaNFew6VK-LzjJWTD4GwmLlk8B-wCceh&fc=20220923065203&ff=20250214170340&v=2.18.0.post9+e462414
source: (((leukemia) OR (lymphoma)) OR (myeloma)) AND (Stanford University[Affiliation])
description: 'CONCLUSION: Allogeneic CD19 CAR T cells demonstrated promising overall
  and durable complete response rates with a manageable safety profile in CD19 CAR
  T-naive patients with R/R LBCL, supporting additional evaluation of cema-cel in
  patients with ...'
disable_comments: true
---
CONCLUSION: Allogeneic CD19 CAR T cells demonstrated promising overall and durable complete response rates with a manageable safety profile in CD19 CAR T-naive patients with R/R LBCL, supporting additional evaluation of cema-cel in patients with ...